MAPK8 and breast cancer: They also demonstrated, in a breast cancer mouse model, that treatment with JNK inhibitor CC_401 disrupted expression of ECM proteins and enhanced the effect of paclitaxel, suggesting that JNK signaling is involved in modulating the niche that allows CSCs to evade chemotherapy and promote metastasis.